Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Guangzhou Anobri Pharmaceutical Co. Ltd. is navigating 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 3 distinct examiners and 3 distinct art units. This one-to-one ratio between the 3 pending office actions and the 3 distinct examiners indicates a highly decentralized prosecution environment. Each active case is being reviewed by a different individual, ensuring independent evaluations across the portfolio.
KRISHNAN, GANAPATHY is the busiest examiner, managing 1 pending office action. With 3 distinct art units, the applicant must prepare for 3 different sets of examination criteria. This lack of overlap means that success in 1 pending office action may not provide a clear roadmap for the others, as each matter is being handled by a different individual in a different specialized group within the Biotechnology & Pharmaceuticals sector. The presence of 3 distinct art units suggests that the company's pharmaceutical research spans several different technical classifications at the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KRISHNAN, GANAPATHY | 1 | 52.7% | +1.3% |
| NIEBAUER, RONALD T | 1 | 40.8% | +34.0% |
| PURDY, KYLE A | 1 | 41.0% | +35.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18294314 | NOVEL CATIONIC LIPID COMPOUNDS | PURDY, KYLE A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18699969 | NOVEL DEUTERATED CYANO COMPOUNDS, PREPARATION METHODS, COMPOSITIONS AND APPLICATIONS | NIEBAUER, RONALD T | — |
| 18294314 | NOVEL CATIONIC LIPID COMPOUNDS | PURDY, KYLE A | — |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| 1658 | 1 |
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18723921 | A SYNERGISTIC PHARMACEUTICAL COMPOSITION AND ITS ANTIVIRAL USE | KRISHNAN, GANAPATHY | 1693 | §103Other | Non-Final OA | — | Pending | Jun 25, 2024 |
| 18699969 | NOVEL DEUTERATED CYANO COMPOUNDS, PREPARATION METHODS, COMPOSITIONS AND APPLICATIONS | NIEBAUER, RONALD T | 1658 | §103§112DP | Non-Final OA | — | Pending | Apr 10, 2024 |
| 18294314 | NOVEL CATIONIC LIPID COMPOUNDS | PURDY, KYLE A | 1611 | §102§103 | Non-Final OA | — | Pending | Feb 01, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGuangzhou Anobri Pharmaceutical Co. Ltd. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Ganapathy Krishnan has the most, with 1 of Guangzhou Anobri Pharmaceutical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
